Om Prakash Ganda, M.B.,B.S., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertriglyceridemia | 3 | 2023 | 293 | 1.480 |
Why?
|
| Diabetic Angiopathies | 11 | 2018 | 806 | 1.170 |
Why?
|
| Diabetes Mellitus | 30 | 2020 | 5892 | 1.130 |
Why?
|
| Hypercholesterolemia | 6 | 2015 | 1145 | 1.080 |
Why?
|
| Cholesterol | 15 | 2023 | 2913 | 0.950 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 7460 | 0.830 |
Why?
|
| Diabetes Mellitus, Type 2 | 21 | 2023 | 12252 | 0.830 |
Why?
|
| Dyslipidemias | 4 | 2018 | 873 | 0.800 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2018 | 3253 | 0.790 |
Why?
|
| Hypolipidemic Agents | 6 | 2018 | 609 | 0.750 |
Why?
|
| Atherosclerosis | 6 | 2023 | 3431 | 0.640 |
Why?
|
| Apolipoproteins B | 2 | 2012 | 386 | 0.640 |
Why?
|
| Triglycerides | 13 | 2023 | 2464 | 0.620 |
Why?
|
| Hypoglycemic Agents | 5 | 2018 | 3110 | 0.550 |
Why?
|
| Cardiovascular Diseases | 10 | 2023 | 15662 | 0.500 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 878 | 0.450 |
Why?
|
| Diabetes Mellitus, Type 1 | 21 | 2012 | 3447 | 0.450 |
Why?
|
| Lipids | 11 | 2018 | 3345 | 0.420 |
Why?
|
| Cholesterol, LDL | 6 | 2023 | 2402 | 0.400 |
Why?
|
| Blood Glucose | 22 | 2016 | 6434 | 0.400 |
Why?
|
| Lipoproteins | 2 | 2023 | 880 | 0.380 |
Why?
|
| Lipid Metabolism | 2 | 2018 | 1904 | 0.340 |
Why?
|
| Fasting | 1 | 2016 | 1610 | 0.330 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 1673 | 0.320 |
Why?
|
| Insulin | 23 | 2016 | 6610 | 0.320 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2010 | 301 | 0.300 |
Why?
|
| Bile Acids and Salts | 1 | 2010 | 400 | 0.300 |
Why?
|
| Niacin | 2 | 2006 | 117 | 0.300 |
Why?
|
| Self Care | 7 | 2018 | 801 | 0.290 |
Why?
|
| Hyperglycemia | 1 | 2016 | 1389 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2018 | 10397 | 0.270 |
Why?
|
| Anticholesteremic Agents | 3 | 2010 | 972 | 0.270 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2007 | 360 | 0.250 |
Why?
|
| Hypertension | 5 | 2016 | 8615 | 0.230 |
Why?
|
| Insulin Resistance | 5 | 2012 | 3982 | 0.220 |
Why?
|
| Diabetes Complications | 5 | 2018 | 1320 | 0.210 |
Why?
|
| Comprehensive Health Care | 2 | 2015 | 123 | 0.200 |
Why?
|
| Islets of Langerhans | 14 | 1989 | 1351 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 9264 | 0.190 |
Why?
|
| Diabetes Mellitus, Lipoatrophic | 1 | 2000 | 9 | 0.180 |
Why?
|
| Prediabetic State | 7 | 2018 | 548 | 0.180 |
Why?
|
| Chromans | 1 | 2000 | 116 | 0.170 |
Why?
|
| Lipodystrophy | 1 | 2000 | 145 | 0.160 |
Why?
|
| Humans | 92 | 2023 | 768887 | 0.160 |
Why?
|
| Psychotherapy, Group | 2 | 2013 | 417 | 0.150 |
Why?
|
| Adiposity | 1 | 2007 | 1895 | 0.140 |
Why?
|
| Public Health | 1 | 2010 | 2680 | 0.140 |
Why?
|
| Thiazolidinediones | 1 | 2000 | 461 | 0.140 |
Why?
|
| Fibrinogen | 2 | 1992 | 892 | 0.140 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2020 | 565 | 0.130 |
Why?
|
| Diseases in Twins | 9 | 1986 | 447 | 0.130 |
Why?
|
| Diet Therapy | 1 | 2016 | 150 | 0.120 |
Why?
|
| Patient Compliance | 3 | 2015 | 2701 | 0.120 |
Why?
|
| Nutrition Policy | 1 | 2018 | 467 | 0.110 |
Why?
|
| Somatostatin | 4 | 1983 | 458 | 0.110 |
Why?
|
| India | 3 | 2016 | 2325 | 0.110 |
Why?
|
| Health Behavior | 2 | 2016 | 2649 | 0.110 |
Why?
|
| Thiazoles | 1 | 2000 | 1542 | 0.100 |
Why?
|
| Obesity | 5 | 2018 | 13087 | 0.100 |
Why?
|
| Basement Membrane | 3 | 1983 | 348 | 0.100 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 1398 | 0.100 |
Why?
|
| Adult | 45 | 2018 | 223818 | 0.100 |
Why?
|
| Phosphatidylcholine-Sterol O-Acyltransferase | 1 | 2011 | 33 | 0.100 |
Why?
|
| Allylamine | 1 | 2010 | 10 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 1447 | 0.090 |
Why?
|
| Middle Aged | 40 | 2018 | 223740 | 0.090 |
Why?
|
| Gastrointestinal Hormones | 2 | 1981 | 101 | 0.090 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 2339 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 1119 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 8055 | 0.080 |
Why?
|
| Twins, Monozygotic | 7 | 1986 | 472 | 0.080 |
Why?
|
| Hyperlipidemias | 3 | 2002 | 773 | 0.080 |
Why?
|
| Diabetes, Gestational | 1 | 2018 | 1260 | 0.080 |
Why?
|
| Mannose | 2 | 1979 | 122 | 0.070 |
Why?
|
| Male | 47 | 2018 | 365249 | 0.070 |
Why?
|
| Glucose Tolerance Test | 9 | 1986 | 1183 | 0.070 |
Why?
|
| Glucagon | 10 | 1986 | 534 | 0.070 |
Why?
|
| United States | 11 | 2018 | 73180 | 0.070 |
Why?
|
| Blood Sedimentation | 1 | 1988 | 236 | 0.070 |
Why?
|
| Lipoproteins, HDL | 4 | 2011 | 682 | 0.070 |
Why?
|
| Disease Management | 1 | 2018 | 2537 | 0.070 |
Why?
|
| Female | 48 | 2018 | 397464 | 0.070 |
Why?
|
| Adenoma, Islet Cell | 3 | 1987 | 72 | 0.070 |
Why?
|
| Albuminuria | 1 | 1991 | 658 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2012 | 2280 | 0.070 |
Why?
|
| Overweight | 1 | 2018 | 2445 | 0.070 |
Why?
|
| Consensus | 1 | 2016 | 3214 | 0.070 |
Why?
|
| Homozygote | 1 | 2011 | 1779 | 0.070 |
Why?
|
| Muscles | 3 | 1983 | 1582 | 0.070 |
Why?
|
| Gemfibrozil | 1 | 2005 | 30 | 0.060 |
Why?
|
| Aged | 22 | 2020 | 171790 | 0.060 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 59738 | 0.060 |
Why?
|
| Risk Factors | 9 | 2016 | 74971 | 0.060 |
Why?
|
| Diabetic Nephropathies | 2 | 1992 | 973 | 0.060 |
Why?
|
| Nutrition Surveys | 1 | 2012 | 1738 | 0.060 |
Why?
|
| Amidines | 1 | 1984 | 28 | 0.060 |
Why?
|
| Emigration and Immigration | 1 | 2007 | 407 | 0.060 |
Why?
|
| Valine | 1 | 2006 | 410 | 0.060 |
Why?
|
| Pentamidine | 1 | 1984 | 44 | 0.060 |
Why?
|
| Health Promotion | 1 | 2016 | 2210 | 0.060 |
Why?
|
| Treatment Outcome | 7 | 2018 | 65485 | 0.060 |
Why?
|
| Cholesterol, HDL | 6 | 2009 | 1820 | 0.060 |
Why?
|
| Glucose | 6 | 1984 | 4352 | 0.060 |
Why?
|
| Tolbutamide | 3 | 1984 | 23 | 0.060 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2006 | 428 | 0.050 |
Why?
|
| Heptanoic Acids | 1 | 2005 | 344 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2015 | 24330 | 0.050 |
Why?
|
| Gastric Inhibitory Polypeptide | 2 | 1981 | 69 | 0.050 |
Why?
|
| Simvastatin | 1 | 2005 | 346 | 0.050 |
Why?
|
| Autoantibodies | 7 | 1989 | 2126 | 0.050 |
Why?
|
| Capillaries | 2 | 1983 | 756 | 0.050 |
Why?
|
| Mutation, Missense | 1 | 2011 | 2592 | 0.050 |
Why?
|
| Triplets | 2 | 1983 | 42 | 0.050 |
Why?
|
| Aging | 1 | 2020 | 8765 | 0.050 |
Why?
|
| Endorphins | 1 | 1981 | 73 | 0.050 |
Why?
|
| Neurotensin | 1 | 1981 | 60 | 0.050 |
Why?
|
| Tetrazoles | 1 | 2006 | 923 | 0.040 |
Why?
|
| Arteriosclerosis | 2 | 2000 | 1056 | 0.040 |
Why?
|
| Exercise | 1 | 2016 | 5953 | 0.040 |
Why?
|
| Diet, Fat-Restricted | 2 | 2012 | 328 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 2003 | 943 | 0.040 |
Why?
|
| Japan | 1 | 2003 | 1418 | 0.040 |
Why?
|
| Twins | 1 | 1980 | 340 | 0.040 |
Why?
|
| Growth Hormone | 2 | 1978 | 573 | 0.040 |
Why?
|
| Pyrroles | 1 | 2005 | 1126 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2012 | 3269 | 0.040 |
Why?
|
| Telemedicine | 1 | 2016 | 3109 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2011 | 3967 | 0.040 |
Why?
|
| Prevalence | 3 | 2016 | 15875 | 0.040 |
Why?
|
| Galactose | 1 | 1979 | 300 | 0.040 |
Why?
|
| Hormones, Ectopic | 1 | 1977 | 37 | 0.040 |
Why?
|
| Fructose | 1 | 1979 | 284 | 0.040 |
Why?
|
| Environment | 1 | 2003 | 1125 | 0.040 |
Why?
|
| China | 1 | 2003 | 2395 | 0.040 |
Why?
|
| Preconception Care | 1 | 2018 | 143 | 0.030 |
Why?
|
| Methylglycosides | 1 | 1976 | 10 | 0.030 |
Why?
|
| Deoxy Sugars | 1 | 1976 | 20 | 0.030 |
Why?
|
| Methylglucosides | 1 | 1976 | 35 | 0.030 |
Why?
|
| Hypoglycemia | 1 | 1984 | 895 | 0.030 |
Why?
|
| Cost Savings | 2 | 2012 | 915 | 0.030 |
Why?
|
| Hormones | 2 | 1980 | 871 | 0.030 |
Why?
|
| Streptozocin | 1 | 1976 | 190 | 0.030 |
Why?
|
| Drug Monitoring | 2 | 2012 | 965 | 0.030 |
Why?
|
| Life Style | 1 | 2007 | 3931 | 0.030 |
Why?
|
| Amino Acids | 3 | 1976 | 1716 | 0.030 |
Why?
|
| Deoxyglucose | 1 | 1976 | 333 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 4 | 1987 | 5443 | 0.030 |
Why?
|
| Nitrogen | 1 | 1976 | 345 | 0.030 |
Why?
|
| Rheumatoid Nodule | 1 | 1974 | 15 | 0.030 |
Why?
|
| Coronary Disease | 2 | 2003 | 5919 | 0.030 |
Why?
|
| Syndrome | 1 | 2000 | 3274 | 0.030 |
Why?
|
| Pravastatin | 1 | 1995 | 393 | 0.030 |
Why?
|
| Rheumatoid Factor | 1 | 1974 | 185 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2018 | 904 | 0.030 |
Why?
|
| Adolescent | 17 | 2012 | 89247 | 0.030 |
Why?
|
| Busulfan | 1 | 1973 | 259 | 0.030 |
Why?
|
| Reference Values | 2 | 2006 | 4941 | 0.030 |
Why?
|
| Skin | 1 | 2006 | 4507 | 0.020 |
Why?
|
| Ethanol | 1 | 1978 | 1332 | 0.020 |
Why?
|
| Educational Status | 2 | 2012 | 2515 | 0.020 |
Why?
|
| Motor Activity | 2 | 2012 | 2722 | 0.020 |
Why?
|
| Proteinuria | 2 | 2011 | 610 | 0.020 |
Why?
|
| Arginine | 2 | 1986 | 932 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 283 | 0.020 |
Why?
|
| Corneal Opacity | 1 | 2011 | 52 | 0.020 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 1978 | 394 | 0.020 |
Why?
|
| Bone Marrow Diseases | 1 | 1973 | 234 | 0.020 |
Why?
|
| Nephrectomy | 1 | 1976 | 949 | 0.020 |
Why?
|
| Fruit | 1 | 2016 | 1165 | 0.020 |
Why?
|
| Vegetables | 1 | 2016 | 1199 | 0.020 |
Why?
|
| Body Composition | 1 | 2000 | 2461 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2016 | 1025 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 1422 | 0.020 |
Why?
|
| Alcoholism | 2 | 1978 | 1981 | 0.020 |
Why?
|
| Smoking Cessation | 2 | 2012 | 2084 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2011 | 305 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2012 | 8559 | 0.020 |
Why?
|
| Adrenal Medulla | 1 | 1989 | 56 | 0.020 |
Why?
|
| Animals | 3 | 2020 | 169408 | 0.020 |
Why?
|
| Pregnancy | 9 | 2018 | 30175 | 0.020 |
Why?
|
| Health Care Costs | 2 | 2012 | 3270 | 0.020 |
Why?
|
| Adaptation, Psychological | 2 | 2012 | 2667 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2016 | 2003 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 1647 | 0.020 |
Why?
|
| Child | 14 | 2012 | 80969 | 0.020 |
Why?
|
| Pyruvates | 3 | 1976 | 83 | 0.020 |
Why?
|
| Antigens | 4 | 1977 | 1444 | 0.020 |
Why?
|
| Liver Diseases | 1 | 1976 | 1305 | 0.020 |
Why?
|
| Injections, Intravenous | 3 | 1984 | 1379 | 0.020 |
Why?
|
| Radioimmunoassay | 3 | 1987 | 862 | 0.020 |
Why?
|
| Physical Fitness | 1 | 2011 | 744 | 0.020 |
Why?
|
| Lactates | 3 | 1976 | 401 | 0.020 |
Why?
|
| Rheumatic Diseases | 1 | 1974 | 663 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 1976 | 1789 | 0.020 |
Why?
|
| Administration, Oral | 3 | 2006 | 4042 | 0.020 |
Why?
|
| alpha-Fetoproteins | 1 | 1987 | 229 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2006 | 10778 | 0.020 |
Why?
|
| Quality of Life | 3 | 2013 | 13510 | 0.020 |
Why?
|
| Motivation | 1 | 2016 | 2030 | 0.020 |
Why?
|
| Body Constitution | 1 | 1986 | 273 | 0.020 |
Why?
|
| Homocysteine | 1 | 2009 | 637 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2016 | 5323 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2009 | 935 | 0.020 |
Why?
|
| HLA Antigens | 2 | 1983 | 1336 | 0.020 |
Why?
|
| Sex Factors | 3 | 2009 | 10641 | 0.010 |
Why?
|
| Somatostatinoma | 1 | 1983 | 10 | 0.010 |
Why?
|
| C-Reactive Protein | 2 | 2009 | 3858 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1992 | 6242 | 0.010 |
Why?
|
| Double-Blind Method | 3 | 2006 | 12469 | 0.010 |
Why?
|
| Alanine | 2 | 1976 | 614 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2006 | 1502 | 0.010 |
Why?
|
| Follow-Up Studies | 3 | 2013 | 39394 | 0.010 |
Why?
|
| Depression | 2 | 2012 | 8240 | 0.010 |
Why?
|
| Blood Pressure | 3 | 2006 | 8541 | 0.010 |
Why?
|
| Insulin Infusion Systems | 1 | 1983 | 221 | 0.010 |
Why?
|
| Young Adult | 3 | 2016 | 60110 | 0.010 |
Why?
|
| Pancreatic Polypeptide | 1 | 1981 | 35 | 0.010 |
Why?
|
| Forearm | 2 | 1976 | 428 | 0.010 |
Why?
|
| Microcirculation | 1 | 2006 | 1281 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1985 | 1439 | 0.010 |
Why?
|
| Enkephalins | 1 | 1981 | 139 | 0.010 |
Why?
|
| Cholecystokinin | 1 | 1981 | 115 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 1627 | 0.010 |
Why?
|
| Peer Group | 1 | 2006 | 698 | 0.010 |
Why?
|
| Probability | 1 | 2006 | 2483 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 4784 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 13427 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1986 | 1895 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2006 | 2108 | 0.010 |
Why?
|
| Prostaglandins | 1 | 1980 | 398 | 0.010 |
Why?
|
| Endpoint Determination | 1 | 2002 | 594 | 0.010 |
Why?
|
| Prospective Studies | 4 | 2016 | 54950 | 0.010 |
Why?
|
| Fibrinolysis | 1 | 1980 | 331 | 0.010 |
Why?
|
| Thyroid (USP) | 1 | 1978 | 3 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1992 | 12093 | 0.010 |
Why?
|
| Thyrotropin-Releasing Hormone | 1 | 1978 | 139 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1978 | 186 | 0.010 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 1 | 1977 | 29 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 4862 | 0.010 |
Why?
|
| Communication | 1 | 2012 | 3908 | 0.010 |
Why?
|
| Physical Exertion | 1 | 1980 | 668 | 0.010 |
Why?
|
| Portacaval Shunt, Surgical | 1 | 1977 | 46 | 0.010 |
Why?
|
| Anxiety | 1 | 2012 | 4677 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1977 | 397 | 0.010 |
Why?
|
| Personality | 1 | 1980 | 560 | 0.010 |
Why?
|
| Mannoheptulose | 1 | 1976 | 1 | 0.010 |
Why?
|
| Alloxan | 1 | 1976 | 13 | 0.010 |
Why?
|
| Cortisone | 1 | 1977 | 90 | 0.010 |
Why?
|
| Social Conditions | 1 | 1977 | 121 | 0.010 |
Why?
|
| Propranolol | 1 | 1978 | 493 | 0.010 |
Why?
|
| Time Factors | 7 | 1984 | 40266 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1978 | 1629 | 0.010 |
Why?
|
| Histocompatibility Antigens | 1 | 1977 | 479 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 1978 | 407 | 0.010 |
Why?
|
| Risk | 3 | 1985 | 9621 | 0.010 |
Why?
|
| Ammonia | 1 | 1976 | 248 | 0.010 |
Why?
|
| Thyrotropin | 1 | 1978 | 834 | 0.010 |
Why?
|
| Hepatic Encephalopathy | 1 | 1976 | 144 | 0.010 |
Why?
|
| Thyroxine | 1 | 1978 | 665 | 0.010 |
Why?
|
| Eye Manifestations | 1 | 1974 | 10 | 0.010 |
Why?
|
| Liver Cirrhosis | 2 | 1976 | 1962 | 0.010 |
Why?
|
| Brachial Artery | 1 | 1976 | 373 | 0.010 |
Why?
|
| Hypothyroidism | 1 | 1978 | 668 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1985 | 2260 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 1980 | 1410 | 0.010 |
Why?
|
| Glutamine | 1 | 1976 | 578 | 0.010 |
Why?
|
| Leukopenia | 1 | 1973 | 212 | 0.010 |
Why?
|
| Glycine | 1 | 1976 | 672 | 0.010 |
Why?
|
| Rats | 2 | 1981 | 23847 | 0.010 |
Why?
|
| Serine | 1 | 1976 | 831 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2006 | 7860 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 11119 | 0.010 |
Why?
|
| Kinetics | 1 | 1979 | 6334 | 0.010 |
Why?
|
| Veins | 1 | 1976 | 769 | 0.010 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 1981 | 1077 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 1977 | 1082 | 0.010 |
Why?
|
| Virus Diseases | 1 | 1977 | 724 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 1974 | 345 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 26384 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1976 | 3056 | 0.010 |
Why?
|
| Leukemia, Myeloid | 1 | 1973 | 693 | 0.010 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1976 | 1124 | 0.010 |
Why?
|
| Blood Platelets | 1 | 1980 | 2479 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 1977 | 1541 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 15955 | 0.000 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1989 | 694 | 0.000 |
Why?
|
| Dexamethasone | 1 | 1974 | 1965 | 0.000 |
Why?
|
| Postmenopause | 1 | 1995 | 2519 | 0.000 |
Why?
|
| HLA-DR4 Antigen | 1 | 1985 | 22 | 0.000 |
Why?
|
| HLA-DR3 Antigen | 1 | 1985 | 24 | 0.000 |
Why?
|
| HLA-DR2 Antigen | 1 | 1985 | 45 | 0.000 |
Why?
|
| Antibodies | 2 | 1984 | 2422 | 0.000 |
Why?
|
| Thrombocytopenia | 1 | 1973 | 1181 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1989 | 2475 | 0.000 |
Why?
|
| Body Mass Index | 1 | 2002 | 13054 | 0.000 |
Why?
|
| Somatostatin-28 | 1 | 1983 | 6 | 0.000 |
Why?
|
| Immunoenzyme Techniques | 1 | 1987 | 1705 | 0.000 |
Why?
|
| HLA-DR Antigens | 1 | 1985 | 609 | 0.000 |
Why?
|
| Smoking | 1 | 1980 | 9094 | 0.000 |
Why?
|
| Chromatography, Gel | 1 | 1983 | 637 | 0.000 |
Why?
|
| Hyperlipoproteinemias | 1 | 1983 | 20 | 0.000 |
Why?
|
| Multiple Myeloma | 1 | 1981 | 5195 | 0.000 |
Why?
|
| Histocompatibility Testing | 1 | 1983 | 716 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1977 | 19023 | 0.000 |
Why?
|
| Age Factors | 2 | 1992 | 18454 | 0.000 |
Why?
|
| Leukemia, Lymphoid | 1 | 1981 | 312 | 0.000 |
Why?
|
| Diet | 1 | 1978 | 8090 | 0.000 |
Why?
|
| Adipose Tissue | 1 | 1971 | 3335 | 0.000 |
Why?
|
| Protein Precursors | 1 | 1983 | 1135 | 0.000 |
Why?
|
| Phenotype | 1 | 1977 | 16735 | 0.000 |
Why?
|
| Child, Preschool | 3 | 1989 | 42684 | 0.000 |
Why?
|
| Pedigree | 1 | 1985 | 4545 | 0.000 |
Why?
|
| Immunoglobulin A | 1 | 1981 | 992 | 0.000 |
Why?
|
| Triiodothyronine | 1 | 1978 | 492 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1976 | 18366 | 0.000 |
Why?
|
| Immunoglobulin M | 1 | 1981 | 1528 | 0.000 |
Why?
|
| Glycerol | 1 | 1975 | 274 | 0.000 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1987 | 2336 | 0.000 |
Why?
|
| Alleles | 1 | 1985 | 6901 | 0.000 |
Why?
|
| Mice | 1 | 1981 | 82074 | 0.000 |
Why?
|
| Dietary Carbohydrates | 1 | 1978 | 896 | 0.000 |
Why?
|
| Blood Cells | 1 | 1975 | 309 | 0.000 |
Why?
|
| Infant | 2 | 1989 | 36541 | 0.000 |
Why?
|
| Dietary Proteins | 1 | 1978 | 960 | 0.000 |
Why?
|
| Lymphoma | 1 | 1981 | 1900 | 0.000 |
Why?
|
| Peptides | 1 | 1983 | 4353 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1987 | 4363 | 0.000 |
Why?
|
| Registries | 1 | 1983 | 8384 | 0.000 |
Why?
|